Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

NCT05930665 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Pleural Mesothelioma

Interventions

DRUG: Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin

Sponsor

Sun Yat-sen University